Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Nov;33(11):1878–1882. doi: 10.1128/aac.33.11.1878

In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae.

P M Mendelman 1, L L Henritzy 1, D O Chaffin 1, K Lent 1, A L Smith 1, T L Stull 1, E A Wiley 1
PMCID: PMC172781  PMID: 2610499

Abstract

The antimicrobial activities of cefixime, cefpodoxime, and ceftibuten were determined with 18 ampicillin-susceptible (Amps), 13 ampicillin-resistant beta-lactamase-producing (AmprBLP), and 7 ampicillin-resistant non-beta-lactamase-producing (AmprNBLP) strains of Haemophilus influenzae. An effect of inoculum density on apparent MIC, the bactericidal activity of these agents, and the targets of the three cephems were determined. The MICs of cefixime, cefpodoxime, and ceftibuten for 90% of the Amps and AmprBLP isolates were 0.04, 0.08, and 0.08 microgram/ml, respectively. In contrast, the MICs for 90% of the AmprNBLP strains were 0.96, 1.92, and 7.68 micrograms/ml. No significant inoculum effect was observed for any group of strains comparing inocula of 10(3) and 10(5) CFU, whereas only the AmprNBLP isolates showed a marked effect at an inoculum of 10(6) CFU. Although bactericidal levels were achieved for the Amps and AmprBLP strains, tolerance to cefixime and ceftibuten was observed. The bactericidal activity for the AmprNBLP strains was limited, with cefixime showing the highest activity of the three cephems. Penicillin-binding proteins 2, 4, and 5 revealed high affinity, with 50% inhibitory concentration levels below the MIC for all three cephems, suggesting that these are important targets of these agents in H. influenzae. We conclude that the cephems are highly active in vitro against Amps and AmprBLP strains of H. influenzae, but less so against AmprNBLP isolates.

Full text

PDF
1879

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergeron M. G., Lavoie G. Y., Boucher F. D. Comparative bactericidal activity of cefixime, carumonam, enoxacin and roxithromycin with those of other antibiotics against resistant Haemophilus influenzae including beta-lactam tolerant strains. J Antimicrob Chemother. 1987 Nov;20(5):663–669. doi: 10.1093/jac/20.5.663. [DOI] [PubMed] [Google Scholar]
  2. Doern G. V., Jorgensen J. H., Thornsberry C., Preston D. A., Tubert T., Redding J. S., Maher L. A. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 1988 Feb;32(2):180–185. doi: 10.1128/aac.32.2.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fuchs P. C., Barry A. L., Jones R. N. Cefixime disk susceptibility test criteria. J Clin Microbiol. 1986 Oct;24(4):647–649. doi: 10.1128/jcm.24.4.647-649.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jones R. N., Barry A. L. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother. 1988 Apr;32(4):443–449. doi: 10.1128/aac.32.4.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones R. N., Barry A. L. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother. 1988 Oct;32(10):1576–1582. doi: 10.1128/aac.32.10.1576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones R. N., Barry A. L. In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition. Diagn Microbiol Infect Dis. 1987 Dec;8(4):245–249. doi: 10.1016/0732-8893(87)90056-3. [DOI] [PubMed] [Google Scholar]
  7. Jorgensen J. H., Doern G. V., Thornsberry C., Preston D. A., Redding J. S., Maher L. A., Tubert T. Susceptibility of multiply resistant Haemophilus influenzae to newer antimicrobial agents. Diagn Microbiol Infect Dis. 1988 Jan;9(1):27–32. doi: 10.1016/0732-8893(88)90057-0. [DOI] [PubMed] [Google Scholar]
  8. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kamimura T., Kojo H., Matsumoto Y., Mine Y., Goto S., Kuwahara S. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother. 1984 Jan;25(1):98–104. doi: 10.1128/aac.25.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Knapp C. C., Sierra-Madero J., Washington J. A. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Antimicrob Agents Chemother. 1988 Dec;32(12):1896–1898. doi: 10.1128/aac.32.12.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kumar A., Kelly K. J. In vitro activity of cefixime (CL284635) and other antimicrobial agents against Haemophilus isolates from pediatric patients. Chemotherapy. 1988;34(1):30–35. doi: 10.1159/000238544. [DOI] [PubMed] [Google Scholar]
  12. Mendelman P. M., Chaffin D. O., Clausen C., Stull T. L., Needham C., Williams J. D., Smith A. L. Failure to detect ampicillin-resistant, non-beta-lactamase-producing Haemophilus influenzae by standard disk susceptibility testing. Antimicrob Agents Chemother. 1986 Aug;30(2):274–280. doi: 10.1128/aac.30.2.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mendelman P. M., Chaffin D. O., Musser J. M., De Groot R., Serfass D. A., Selander R. K. Genetic and phenotypic diversity among ampicillin-resistant, non-beta-lactamase-producing, nontypeable Haemophilus influenzae isolates. Infect Immun. 1987 Nov;55(11):2585–2589. doi: 10.1128/iai.55.11.2585-2589.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mendelman P. M., Chaffin D. O., Stull T. L., Rubens C. E., Mack K. D., Smith A. L. Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob Agents Chemother. 1984 Aug;26(2):235–244. doi: 10.1128/aac.26.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Powell M., Williams J. D. In vitro susceptibility of Haemophilus influenzae to cefixime. Antimicrob Agents Chemother. 1987 Nov;31(11):1841–1842. doi: 10.1128/aac.31.11.1841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Serfass D. A., Mendelman P. M., Chaffin D. O., Needham C. A. Ampicillin resistance and penicillin-binding proteins of Haemophilus influenzae. J Gen Microbiol. 1986 Oct;132(10):2855–2861. doi: 10.1099/00221287-132-10-2855. [DOI] [PubMed] [Google Scholar]
  17. Shigi Y., Matsumoto Y., Kaizu M., Fujishita Y., Kojo H. Mechanism of action of the new orally active cephalosporin FK027. J Antibiot (Tokyo) 1984 Jul;37(7):790–796. doi: 10.7164/antibiotics.37.790. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES